| Lizenz: Creative Commons Namensnennung-NichtKommerziell 4.0 International PDF - Veröffentlichte Version (565kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-783378
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.78337
Zusammenfassung
Sleep-disordered breathing (SDB) represents a modifiable treatment target in patients with heart failure (HF). Despite the evolution of positive airway pressure (PAP) therapy over the past several decades, randomised controlled trials have not demonstrated a consistent benefit in reducing mortality or hospital admissions related to HF. As a result, the use of PAP therapy has been primarily ...

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik